Amylyx is a pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders. They incorporate unconventional approaches through strong partnerships with industry leaders, scientists, doctors, and organizations by working collaboratively across everything they do to positively impact the lives of patients and their families.
Kineticos Value Add
Kineticos Venture Partner, Derek Hennecke, has served as an investor and strategic advisor since the seed stage of Amylyx.
Team: Executives and advisors are experts within Neurosciences and key opinion leaders in the market
Platform: Novel combination therapy with compelling clinical data showing improvement in patients with ALS
Unmet Need: Neurodegenerative disorders, particularly ALS, have poor treatment options, with nearly 9000 ALS patients per year